Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: A Retrospective Cohort Analysis of up to 4 Years
Open Access
- 18 March 2025
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (4) , 949-962
Abstract
Introduction Psoriasis, a chronic inflammatory skin disease, affects approximately one million Canadians, with plaque psoriasis (PsO) being the most common subtype. While brodalumab has shown efficacy and safety in phase III clinical trials, Canadian real-world evidence remains limited. This retrospective cohort study aims to report on the real-world outcomes of Canadian patients with PsO who initiated treatment with brodalumab within the 4-year period following its approval by Health Canada. Methods Data from patients with PsO initiating brodalumab treatment in the Canadian patient support program between July 1, 2018 and June 30, 2022 were analyzed. The primary objective evaluated the proportion of patients achieving a 100% reduction in the Psoriasis Area and Severity Index (PASI 100) at selected time windows. Secondary and exploratory objectives included assessing the 90% reduction in PASI score (PASI 90), changes from baseline in mean PASI, body surface area (BSA), and Dermatology Life Quality Index (DLQI) scores, as well as treatment persistence. Results A total of 2482 patients (58.5% male; mean age 51.0 years) were included, with over half being biologic-naïve (56.9%). In a subset of patients with baseline and at least one follow-up data, 66.1% and 53.2% achieved PASI 90 and PASI 100, respectively, within the first 3 months. These rates were sustained, with 68.1% and 52.2% achieving PASI 90 and PASI 100, respectively, beyond 24 months. Significant improvements from baseline were observed for PASI, BSA, and DLQI scores, and these improvements were maintained over time. Among all patients, the 1-year persistence rate was 73.4%. Conclusions This study provides valuable insights into the profile of patients treated with brodalumab in Canada. While the rapid and sustained skin clearance, as well as improvements in PASI, BSA, and DLQI scores, support the therapeutic benefits of brodalumab beyond clinical trials, further research on long-term effectiveness and safety is warranted.Keywords
Funding Information
- Bausch Health, Canada Inc.
This publication has 20 references indexed in Scilit:
- Brodalumab: 5-Year US Pharmacovigilance ReportDermatology and Therapy, 2024
- Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBestJournal of Dermatological Treatment, 2024
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysisCochrane Database of Systematic Reviews, 2023
- Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life settingDermatologic Therapy, 2022
- Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-AnalysisDermatology and Therapy, 2022
- Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-AnalysisDermatology and Therapy, 2021
- Psoriasis Prevalence and Severity by Expert ElicitationDermatology and Therapy, 2021
- Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Population‐Based StudyArthritis Care & Research, 2019
- A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasisBritish Journal of Dermatology, 2016
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in PsoriasisNew England Journal of Medicine, 2015